What i2020 Accelerator does

i2020 Accelerator is a drug discovery accelerator that co-creates early-stage biotechnology companies in four therapeutic areas: inflammation, oncology, central nervous system disorders, and infectious diseases. Inaugurated in 2017 and launched in January 2018 with up to $30 million of backing from Torrey Pines Investment, the firm takes majority equity positions in newly created portfolio entities and operates a two-year acceleration model intended to move programs from concept to a value-creating milestone before exit or further financing. The company serves emerging biotech founders and scientific entrepreneurs by providing capital, infrastructure, and operational support rather than selling products directly to end customers.

The company's core technology infrastructure is the Loch platform, which integrates computational drug design, screening, and chemistry workflows. i2020 delivers these capabilities through technology partnerships rather than purely internal build — most notably with Molsoft LLC for AI-driven molecular modeling, computer-aided drug design, and giga-screening, and with ChemDiv Inc. for chemistry and compound library access. By 2023, the platform supported 14+ portfolio companies, with cumulative funding across those companies exceeding $100 million, and the company has stated an ambition to launch 20–30 drug discovery programs over its operating horizon.

Commercially, i2020 generates returns primarily through equity appreciation in portfolio companies, supplemented by co-investment capital from partners such as OrbiMed and BioGeneration Ventures. The firm operates from three offices — San Diego (headquarters), Cambridge, Massachusetts, and Basel, Switzerland — and is legally organized as T123 LLC. In 2023, i2020 was integrated into the Expert Systems integrated accelerator platform, consolidating it with related investment vehicles under a broader portfolio strategy. Revenue is not publicly disclosed, and the business model is therefore best characterized as a fund-like accelerator with capital-intensive, exit-driven return mechanics.

Name

i2020 Accelerator

Legal name

T123 LLC

Website

https://i2020accelerator.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

i2020 Accelerator is a drug discovery accelerator that co-creates biotech programs in inflammation, oncology, CNS, and infectious diseases, using its Loch platform and AI/computational partnerships to support 14+ portfolio companies across San Diego, Cambridge, and Basel.

Ownership category

akta.pro rank

Product category

Biotech Accelerator / Drug Discovery Investment Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Drug discovery accelerator
• Early-stage biotech investing
• Oncology discovery programs
• AI drug design platform
• Venture-backed biotech incubation

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Accelerator Program Returns: As an accelerator backed by Torrey Pines Investment, i2020 generates returns through equity stakes and co-development agreements with portfolio companies. The accelerator takes equity in early-stage drug discovery programs and earns returns upon successful development milestones or exit events.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

i2020 Accelerator is a drug discovery accelerator that provides seed funding, R&D expertise, and access to a global scientific network to co-create early-stage small-molecule drug discovery programs with biotech startups. The accelerator takes equity stakes in selected programs and drives them toward advanced lead and clinical candidate stage within a two-year framework, with a planned portfolio of 20-30 diverse programs across oncology, immunology, inflammation, CNS, and infectious diseases.

Product overview

i2020 Accelerator is a drug discovery accelerator program that does not offer a standalone software product. Instead, it operates as an investment and partnership vehicle that accelerates early-stage drug discovery programs through funding, scientific expertise, and access to a global resource network. The core service involves co-creating drug discovery programs with biotech companies, helping them advance from early research to advanced lead compounds and clinical candidates within a two-year timeframe. The company partners with research organizations (Molsoft LLC for AI and computer-aided drug design, ChemDiv Inc. for drug discovery solutions) to support portfolio companies developing treatments across oncology, immunology, infectious diseases, CNS/neurology, inflammation, and autoimmune diseases. Key portfolio programs include the Loch platform (multiple oncology-focused companies), as well as investments in companies like Stelvio Therapeutics (epigenetic platform for glioblastoma), Snap Bio (selective kinase inhibitors), Eilean Therapeutics (hematological cancers), and Trawsfynydd Therapeutics (virology).

Differentiator

Problem solved

Functional benefit

Products and services

• i2020 Accelerator Program Drug discovery accelerator program that provides seed funding, R&D expertise, and access to a global scientific network to co-create early-stage small-molecule drug discovery programs with biotech startups, with a target of 20-30 diverse drug discovery programs.
• Loch Platform

Quantifiable outcome

• Accelerates drug discovery programs to advanced lead and clinical candidate level within two-year timeframe
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and major.

• Expert Systems InccoreStrategic or Co-development Partner · 1 January 2023Consulting platform for drug discovery and development program selection, prioritization, design, execution and market positioning. Offers highly customized solutions for pharma and biotech in oncology, inflammation, immunology, cardiometabolic, neurology and infectious disease therapeutic areas. i2020 is part of the Expert Systems integrated accelerator platform.
• University of Turku (UTU)majorStrategic or Co-development Partner · 1 January 2019Third largest university in Finland with 25,000 students and personnel. i2020 invested in a cutting-edge research program studying previously unrecognized protein-protein interactions that disrupt NMDA receptor signaling pathways for neurodegenerative conditions and neuropathic pain. ChemDiv provides scientific expertise as part of the collaboration.
• Molsoft LLCcoreTechnology or IntegrationLeading provider of tools, databases and consulting services in structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and animation, and rational drug design. Provides AI and computer-aided drug design platform supporting the Loch platform and its programs.
• ChemDiv Inc.coreTechnology or IntegrationRecognized global leader in drug discovery solutions with over 29 years of experience. Delivered hundreds of leads, drug candidates and new drugs in CNS, oncology, virology, inflammation, cardiometabolic and immunology. Provides integrated drug discovery platform and risk-share collaborative platforms for i2020 portfolio companies.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• OrbiMed Advisors: OrbiMed is a $19B+ AUM healthcare investment firm that co-invests in i2020's portfolio companies (Loch platform, Trawsfynydd, Brenig). As i2020's most significant financial partner, OrbiMed is structurally comparable but operates at a much larger scale across all stages of healthcare investing, not purely accelerator creation.

Broad incumbents

• RA Capital Management: RA Capital is a crossover healthcare investor with both early-stage creation activities and late-stage public/private investments. While i2020 focuses exclusively on early-stage creation, RA Capital's TechAtlas and creation-focused funds represent a broader incumbent in the same biotech acceleration ecosystem.
• BridgeBio Pharma: BridgeBio is a clinical-stage biotech company that originated from a venture creation model similar in spirit to i2020's accelerator framework. While BridgeBio has progressed to a commercial-stage operating company, its origin as a multi-program creation engine makes it a useful comparable for the platform approach i2020 employs across the Loch platform.

Direct peers

• Atlas Venture: Atlas Venture builds biotech companies from inception through a "venture creation" model with a strong focus on early-stage drug discovery and platform technologies. Both i2020 and Atlas follow a similar playbook of seed-creation-stage investments in therapeutic programs with co-investor syndicates.
• ARCH Venture Partners: ARCH Venture Partners is a deep-tech and biotech-focused VC that creates and funds early-stage life sciences companies, often co-founding them with academic founders. ARCH shares i2020's model of building companies around novel science in partnership with co-investors and operating partners.
• Apple Tree Partners: Apple Tree Partners is a healthcare-focused venture firm that builds biotech companies from the ground up with dedicated scientific and operating teams. Both ATP and i2020 follow a company-creation approach, often co-founding therapeutic startups with internal R&D capabilities before partnering with larger investors.
• SV Health Investors: SV Health Investors is a transatlantic healthcare VC that builds biotech companies via its Dementia Discovery Fund and other specialized vehicles. Like i2020, SV focuses on first-in-class therapeutics in high-unmet-need areas (neurology, oncology) and uses a creation-driven model with co-investor syndicates.
• Flagship Pioneering: Flagship Pioneering is a bioplatform company that creates and develops first-in-class biotech companies, most notably Moderna. Like i2020, it operates a creation engine model that builds companies around breakthrough science and partners with major investors, making it the closest direct comparable in the biotech accelerator space.
• BioGeneration Ventures (BGV): BGV is a European early-stage biotech VC that co-invests with i2020 and OrbiMed (e.g., Brenig Therapeutics). It operates a similar creation-focused model targeting first-in-class European biotech, making it both a partner and a structural peer in the early-stage European biotech accelerator segment.
• Petri Bio: Petri is a biotech creation platform backed by Section32 that builds early-stage companies around breakthrough science. It operates as a direct accelerator-style peer to i2020, with similar emphasis on first-in-class biology and therapeutic area breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/i2020-accelerator

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about i2020 Accelerator